Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Nitric Oxide in the news, again
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
Post by Red~Oneon Feb 04, 2022 3:46pm
299 Views
Post# 34399269

Nitric Oxide in the news, again

Nitric Oxide in the news, againInhaled Nitric Oxide Can Kill COVID-Causing Coronavirus, Prevent Its Attachment to Human Cells: Indian Researchers
By IANS12 hours agoTWC India
“A study involving doctors and scientists has found that inhaled Nitric Oxide (iNO) is virucidal and kills the SARS-CoV-2 virus, while also preventing its effective attachment to human host cells.
The study was done by doctors of the Amrita Hospital in Kochi, and scientists from the School of Biotechnology at Amrita Vishwa Vidyapeetham.”


https://weather.com/en-IN/india/coronavirus/news/2022-02-04-inhaled-nitric-oxide-can-kill-covid19-causing-coronavirus

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities